Compare Alliant Energy Corporation (LNT) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs McKesson Corporation — how do they compare? Alliant Energy Corporation trades at $65.85 (market cap $16.99B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 6.4× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays the higher dividend (3.27%). Which is the better fit depends on your goals — on Pluang, investors hold Alliant Energy Corporation for 64 Days and McKesson Corporation for 74 Days on average.
| LNT | MCK | |
|---|---|---|
Market Cap | $16.99B | $108.46B |
Volume | 2,488,387 | 712,607 |
Sector | Utilities | Health |
52-Week High | $78.03 | $995.69 |
52-Week Low | $63.21 | $725.17 |
Typical Hold Time | 64 Days | 74 Days |
Enterprise Value | $29.08B | $115.00B |
Dividend Yield | 3.27% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alliant Energy (LNT) trades at $65.50, up 0.44% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with Q2 2026 EPS beating expectations at $0.65 and consistent revenue growth to $4.36B in 2025. Analyst consensus is positive with a $77.00 price target and 52% buy ratings. Recent institutional activity includes significant purchases by California State Teachers Retirement System and Nykredit A/S.
LNT presents a compelling investment case with stable utility operations, 23-year dividend growth, and a $13.4B capital investment plan supporting 5-7% earnings growth. Key risks include rising debt levels (debt-to-asset ratio increased to 48.48% in 2025) and sensitivity to interest rate changes. The stock offers defensive value with current momentum favoring upside toward analyst targets.
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
